Cystic Lung Diseases Causing Spontaneous Pneumothorax

Chen Zhang

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Received: May 5, 2022 | Revised: June 14, 2022 | Accepted: June 17, 2022 | Published: June 28, 2022

Abstract

Surgical specimens resulting from a spontaneous pneumothorax (SP) are commonly encountered in the general surgical pathology practice. Many of the SP cases are primary pneumothorax with no underlying lung diseases. Specimens with primary pneumothorax show nonspecific pneumothorax-related changes, which are important to recognize to exclude the true underlying lung diseases. A variety of disease entities may lead to diffuse cystic changes in the lungs, causing secondary pneumothorax. Some of the diseases are progressive and can cause irreversible damage to the lungs if not treated timely. Diagnosis of cystic lung diseases causing secondary pneumothorax is important for the treatment of the diseases and the prevention of future episodes of pneumothorax. Lymphangioleiomyomatosis and Langerhans cell histiocytosis are two common conditions causing diffuse cystic changes in the lungs. They are discussed in greater detail in this review, given their overlapping features in patient characteristics, radiological findings, and pathologic findings.

Citation of this article: Zhang C. Cystic Lung Diseases Causing Spontaneous Pneumothorax. J Clin Transl Pathol 2022;2(2):48–52. doi: 10.14218/JCTP.2022.00011.

Introduction

Spontaneous pneumothorax (SP) is defined as the presence of air in the pleural cavity without obvious clinical history of trauma or iatrogenic causes. SP is not uncommon, and the incidence rate is about 20 cases per year per 100,000 population. Most cases of SP can resolve following medical management, including observation, aspiration of air with tiny needles, and chest tube placements. Some patients with SP that failed medical management may undergo surgical interventions of pleurodesis with blebectomy. When underlying lung parenchymal diseases are suspected, a wedge lung biopsy may be performed at the time of pleurodesis. While many patients with SP cases have no underlying lung parenchymal diseases, i.e., primary pneumothorax, pleural abnormalities, and reactive changes are almost always present in biopsies. A variety of disease entities may lead to diffuse cystic changes in the lungs, causing secondary pneumothorax. It is important to recognize pneumothorax-related nonspecific changes, as well as underlying cystic lung diseases that cause secondary pneumothorax.

Primary pneumothorax

About 61–85% of the SP cases belong to the category of primary pneumothorax (PP), which is defined as SP with no underlying lung diseases. PP usually occurs in young men with tall and thin body habits and is more common in cigarette smokers. These patients develop air accumulation in the pleura (bleb) and distal/peripheral lungs (bullae). The etiology is unknown, although some genetic and environmental risk factors have been implicated in several studies. The blebs and bullae may rupture and lead to pneumothorax, commonly due to strenuous exercise or weightlifting activities. While the majority of the patients with PP are successfully managed medically, surgical specimens from these patients are still encountered occasionally. PP is a diagnosis of exclusion. Specimens from these patients will show a spectrum of pneumothorax-related changes, which are important to recognize to exclude the true underlying lung diseases. The pneumothorax-related changes include pleural fibrosis with or without blebs, thick-walled blood vessels, and eosinophilic-rich chronic inflammation. The underlying lung parenchyma may show distal acinar emphysema and reactive pneumocyte hyperplasia.

Secondary pneumothorax

Around 15–39% of the patients with SP have underlying lung diseases, which are demonstrated on radiologic imaging as diffuse cystic changes of the lung parenchyma. Many neoplastic and non-neoplastic conditions in the lungs may result in cystic changes, including emphysema, honeycomb changes due to usual interstitial pneumonia or chronic hypersensitivity pneumonia, long-standing pulmonary sarcoidosis, diffuse bronchiectasis, genetic disorders such as Birt-Hogg-Dubé syndrome, infectious diseases such as Pneumocystis pneumonia, and slow-growing malignancies such as low-grade sarcomas and MALT lymphoma. Aside from sarcomas and lymphomas, most of these conditions causing diffuse cystic changes in the lungs are diagnosed clinically and radiologically without the necessity of biopsies. Lymphangioleiomyomatosis (LAM) and Langerhans cell histiocytosis (LCH) are two conditions causing diffuse cystic changes in the lungs, which commonly present as spontaneous pneumothorax and require surgical interven-
LAM

LAM is defined as a locally destructive mesenchymal neoplasm per WHO classification. It is a rare disorder characterized by the proliferation of smooth muscle-like cells (LAM cells) throughout the interstitium of the lung, resembling spread via the lymphatics. Proliferating LAM cells form cellular clusters and cysts, destroying healthy lung parenchyma. Some cases of LAM are present in the setting of tuber sclerosis complex (TSC-LAM), but the majority of cases are sporadic (S-LAM). In both situations, the neoplastic proliferation of LAM cells is caused by the growth-activating mutations in the TSC1 and TSC2 genes.12,13 In TSC-LAM, mutations are present in all cells including the germ line (first hit) and neoplastic cells (second hit). Patients with TSC-LAM may have other TSC-associated tumors such as cardiac hamartoma, renal angiomylipoma, and brain subependymal giant cell astrocytoma.14 Mutations only occur in neoplastic cells (first and second hits) in S-LAM.

Clinically, LAM, especially the sporadic forms, occurs almost exclusively in women, most commonly women of reproductive ages. Most patients with early-stage diseases are asymptomatic. The most common presenting symptom is progressive shortness of breath on exertions. About one-third of patients with LAM present with spontaneous pneumothorax. The pulmonary function continues to decline with the progression of the disease. Chest CT imaging shows multiple air-filled, thin-walled cysts of variable size throughout the entirety of the lung parenchyma. Reticulation due to fibrosis can be prominent at the end stage of the disease.

Microscopically, LAMs cells are spindled to epithelioid, forming cellular clusters, often associated with thin-walled cysts (Fig. 1). There is no significant cytologic atypia, mitotic activity, or necrosis. LAMS cells are usually positive for smooth muscle actin, desmin, estrogen receptor, and HMB45. The expression of the progesterone receptor is frequently higher than that of the estrogen receptor.15 Cathepsin K is a papain-like cysteine protease that is commonly used in the diagnosis of perivascular epithelioid cells (PECs) tumors. A recent study shows that cathepsin K is a more sensitive marker than HMB45 in diagnosing pulmonary LAM.16 LAM cells resemble PECs on morphology and immunoprofile; however, the cell and organ origin of LAM cells is unclear. Benign metastasizing leiomyoma (BML), a rare disorder in women with a history of uterine leiomyoma, resembles LAM because they both show smooth muscle-like morphology, and express SMA and ER/PR, and can undergo cystic change. However, BMLs generally do not express HMB45 and cathepsin K, and they do not harbor mutations in the TSC1 and TSC2 genes.

The proteins tuberin and hamartin encoded by TSC genes are inactivators of mTOR, therefore inactivating mutations in TSC genes leads to increased mTOR activity. Some patients with LAMs benefit from treatments with mTOR inhibitors such as sirolimus, which suppresses disease progression, stabilizes lung function, and improves the quality of life.17,18 End-stage diseases are treated with lung transplantation, although Recurrence of LAM in the grafts has been reported.19-21

LCH

LCH is defined as a proliferative, usually clonal, disorder of Langerhans cells, with associated interstitial changes in the lung tissue per WHO classification. It is characterized by peribronchiolar accumulation of Langerhans cells, which are specialized epithelium-associated dendritic cells regulating mucosal immunity of the airways. Cigarette smoking induces the production and activation of cytokines such as GM-CSF and TGF-β, which activate the proliferation of Langerhans cells.22,23 Persistent activation of Langerhans cells further recruit other immune cells, forming peribronchiolar cellular nodules. These cellular nodules undergo cystic changes and fibrosis over time, destroying the lung parenchyma.

LCH occurs in young adult smokers. About 2/3 of patients with LCH have respiratory symptoms such as shortness of breath and cough. About 16% of patients with LCH present with spontaneous pneumothorax.24 The disease is limited to the lungs in most cases of LCH, but a small proportion of patients present with symptoms secondary to diseases outside of the thorax. Characteristic radiologic imaging findings include nodular infiltrates and cystic changes that are predominantly in the upper and middle lobes of the lung.25

Microscopically, the diagnosis of LCH relies on identifying the peribronchiolar cellular lesions, which consist of LCs, histiocytes, lymphocytes, and eosinophils (Fig. 2). LCH is also known as eosinophilic granuloma because of the frequent presence of abundant eosinophils. However, the absence of eosinophils does not exclude this diagnosis. LCs are histiocyte-like cells with abundant pale, eosinophilic cytoplasm, characteristic indented/folded nuclei, frequent nuclear grooves, and intranuclear inclusions. The other smoking-related changes such as emphysematous change and accumulation of pigmented alveolar macrophages within the lumens of terminal bronchioles and adjacent alveolar spaces (respiratory bronchiolitis) are often present. In long-standing disease of LCH, there may show cysts and stellate scars without obvious cellular lesions (so-called burnt-out LCH). In such a situation, immunohistochemical stains may be helpful to highlight the LCs in small aggregate and single-cell forms. LCs stain positively for S100, CD1a, and Langerin.26 Electron microscopy study demonstrates cytoplasmic tennis racquet-shaped Birbeck granules in LCs.27 Mutations of BRAF or MAP2K1 genes in lesional LCH are seen in up to 50% of cases.28,29 The most identified mutation is BRAF V600E, which is also prevalent in many other

---

Table 1. Comparison between LAM and LCH

|          | LAM                  | LCH                  |
|----------|----------------------|----------------------|
| M:F      | M < F                | M = F                |
| IHC markers | HMB45, SMA, PR, cathepsin K | S-100, CD1a, langerin |
| Treatment | mTOR inhibitors; lung transplantation | Smoking cessation; steroids |
| Prognosis | Progressive          | Good                 |

IHC, immunohistochemistry; LAM, lymphangioleiomyomatosis; LCH, Langerhans cell histiocytosis; mTOR, mammalian target of rapamycin.
Zhang C.: Pneumothorax and cystic lung diseases

The key management strategy of pulmonary LCH is smoking cessation and avoidance of second-hand smoke exposure, which stabilize disease progression, sometimes induce regression and even complete resolution of the disease. Short-term corticosteroids in a combination of chemotherapy agents are effective in the improvement of lung function in some patients with progressive disease despite smoking cessation. Patients with identified causative mutations may be treated with targeted therapies such as BRAF inhibitors. The prognosis of LCH is overall good but variable. The majority of the patients with LCH experience a very little decline in lung function after smoking cessation, but still, some patients develop progressive lung disease with end-stage fibrosis requiring lung transplantation.

Conclusions

When interpretate surgical specimens resulting from SP, it is important to recognize pneumothorax-related nonspecific changes, as well as underlying cystic lung diseases that cause secondary pneumothorax. LAM and LCH both occur in young adults presenting with SP, and they can be difficult to differentiate clinically, radiologically, and even histologically, especially at the late, fibrotic stages of the diseases. The key to the differentiation on biopsy is to identify the cellular lesions, which are diagnostic for the diseases with the help of a few immunohistochemical markers (Table 1). The differentiation of the two diseases is important given the vastly different management and prognosis.

Acknowledgments

None.

Funding

None.

Conflict of interest

None.

Author contributions

Dr. Zhang is the sole author of this article.
Zhang C.: Pneumothorax and cystic lung diseases

References

1. Noppen M. Spontaneous pneumothorax: epidemiology, pathophysiology and cause. Eur Respir Rev 2010;19(117):217–219. doi:10.1183/09059180.0005310, PMID:20956196.

2. Sahn SA, Heffner JE. Spontaneous pneumothorax. N Engl J Med 2000;342(12):868–874. doi:10.1056/NEJM200003233421207, PMID:10725792.

3. Tschopp JM, Rami-Porta R, Noppen M, Astoul P. Management of spontaneous pneumothorax: state of the art. Eur Respir J 2006;28(3):637–650. doi:10.1183/09031936.06.00014206, PMID:16946095.

4. MacDuff A, Arnold A, Harvey J, BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl 2):ii18–ii31. doi:10.1136/thx.2010.136986, PMID:20696690.

5. Noppen M. Management of primary spontaneous pneumothorax. Curr Opin Pulm Med 2003;9(4):272–275. doi:10.1097/00063198-200307000-00005, PMID:12806239.

6. Askin FB, McCann BG, Kuhn C. Reactive eosinophilic pleuritis: a lesion to be distinguished from pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1977;101(4):187–191. PMID:576785.

7. Cyr PV, Vincic L, Kay JM. Pulmonary vasculopathy in idiopathic spontaneous pneumothorax in young subjects. Arch Pathol Lab Med 2000;124(5):717–720. doi:10.5858/2000-124-0717-PVILSP, PMID:10782154.

8. De Smedt A, Vanderlinden E, Demanet C, De Waele M, Goossens A, Noppen M. Characterisation of pleural inflammation occurring after primary spontaneous pneumothorax. Eur Respir J 2004;23(6):986–900. doi:10.1183/09031936.04.00079304, PMID:15219004.

9. Schneider F, Murali R, Veriald KL, Tazelaar HD, Leslie KO. Approach to lung biopsies from patients with pneumothorax. Arch Pathol Lab Med 2014;138(2):257–265. doi:10.5858/arpa.2013-0091-RA, PMID:24476522.

10. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J, Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246(3):697–722. doi:10.1148/radiol.2462070712, PMID:18195376.

11. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangiomeylomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012;186(12):1210–1212. doi:10.1164/rccm.201205-0848OE, PMID:23250499.

12. Strizheva GD, Carsillo T, Kruper WD, Sullivan EJ, Ryu JH, Henske EP. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomatosis. Am J Respir Crit Care Med 2001;163(1):253–258. doi:10.1164/rccm.163.1.2005004, PMID:11208563.

13. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangiomeylomatosis. Proc Natl Acad Sci U S A 2000;97(11):6085–6090. doi:10.1073/pnas.97.11.6085, PMID:10823953.

14. Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers 2016;2:16035. doi:10.1038/nrdp.2016.35, PMID:27226234.

15. Gao L, Yue MM, Davis J, Hysak E, Schuger L. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch 2014;464(4):495–503. doi:10.1007/s00428-014-1559-9, PMID:24573092.

16. Rolim I, Makupson M, Lovrenski A, Farver C, Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis. Appl Immunohistochem Mol Morphol 2022;30(2):108–112. doi:10.1097/PAI.0000000000000968, PMID:34433182.

17. Neurohr C, Hoffmann AL, Huppmann F, Herrera VA, Ihle F, Leuschner S, et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangiomeylomatosis? Respir Res 2011;12:66. doi:10.1186/1465-9921-12-66, PMID:21600334.

18. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364(17):1595–1606. doi:10.1056/NEJMoa1100391, PMID:21410393.

19. McCormack FX, Gupta N, Finlay GR, Young LA, Teixeira-DaSilva AM, Glassgow CG, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangiomeylomatosis Diagno.
Zhang C.: Pneumothorax and cystic lung diseases

flammatory and infectious diseases. Am J Surg Pathol 2007;31(6):947–952. doi:10.1097/01.pas.0000249443.82971.bb, PMID:17527085.
[27] Travis WD, Borok Z, Roun JH, Zhang J, Feuerstein I, Ferrans VJ, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 1993;17(10):971–986. doi:10.1097/00000478-199310000-00002, PMID:8372949.
[28] Sahn K, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012;120(12):e28–34. doi:10.1182/blood-2012-06-429597, PMID:22859608.
[29] Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014;124(10):1655–1658. doi:10.1182/blood-2014-05-577361, PMID:24982505.
[30] Mogulkoc N, Veral A, Bishop PW, Bayinindir U, Pickering CA, Egan JJ. Pulmonary Langerhans’ cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999;115(5):1452–1455. doi:10.1378/chest.115.5.1452, PMID:10334170.
[31] Lorillon G, Bergeron A, Detourmignies L, Jouneau S, Wallaert B, Frija J, et al. Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med 2012;186(9):930–932. doi:10.1164/rccm.186.9.930, PMID:23118088.
[32] Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013;8:72. doi:10.1186/1750-1172-8-72, PMID:23672541.